Avicanna Inc. will host its first Canadian educational symposium, The Emergence of Biopharmaceutical Cannabinoids – From Research & Development to Clinical Translation.

The exclusive, invitation-only event for Canadian and international clinical and research experts, industry experts and Canadian medical community, will be held at MaRS, the epicenter of medical innovation in Canada, in Toronto on March 25 2019.

The symposium will address current gaps within “medical cannabis”, including safety and toxicology concerns, as well as challenges in the rapidly evolving industry. The agenda will cover recent and prominent developments in the cannabinoid research field, an overview of cannabinoids as active pharmaceutical ingredients, their challenges in formulation development and their potential role in several therapeutic areas.

It will also highlight Avicanna’s ongoing studies in a variety of therapeutic areas, including oncology, neurology, pain management and dermatology, which are being conducted in collaboration with a number of leading academic health science institutions in Canada and internationally.

Click on each section of the agenda below to view more details of each session. #AvicannaEBC


Section 1: Cannabinoids and Formulations
Chair: Dr. Chandra Panchal, Axcelon Biopolymers

8:30 a.m.

Welcome and Key Note Remarks Dr. Christine Allen, Professor, Leslie Dan Faculty of Pharmacy, University of Toronto and Chief Scientific Officer, Avicanna Inc.

8:50 a.m.

An Introduction to Cannabinoid Formulation Development Dr. Frantz Le Dévédec, Avicanna Inc.

9:10 a.m.

Toxicology and Pharmacology of Cannabinoids Dr. Ruth Ross, University of Toronto
Panelists: Dr. Lakshmi Kotra, University of Toronto; Dr. Janeth Mora, Avicanna Inc.; and Dr. Andres Zuluaga, University of Antioquia

9:50 a.m.


Section 2: Regulatory Affairs and the Emerging Industry
Moderator: Dr. Hance Clarke, MD, PhD, University Health Network

10:00 a.m.

Canada’s Leadership Position in the Emerging Global Industry Aras Azadian, Avicanna Inc.
Panelists: Javier Hasse, Benzinga; Michael Astone, BMO Capital Markets; Stephen Murphy, Prohibition Partners; and Dr. Kaivan Talachian, CannTrust Inc.

10:50 a.m.

Canadian Regulatory Landscape Dr. Edith Gorecki, dicentra

11:10 a.m.

Clinical Development Plan for Cannabinoids Dr. Humberto Reynales, Centro De Atención E Investigación Médica

11:30 a.m.

Healthcare Practitioner Perspective Alex Chan, PharmAct Health Solutions
Panelists: Dr. Carlo DeAngelis, Sunnybrook Health Sciences Centre; Dr. Carlos Maldonado, Universidad Nacional; and Dr. Nimish Purohit, Entourage Clinic

12:10 p.m.


1:00 p.m.

Natural Cannabinoid Active Pharmaceutical Ingredients: From Seed to API Samantha Watt, Avicanna Inc.
Panelists: Dr. David Kideckel, AltaCorp Capital Inc.; Ignacio Perlata, University of Buenos Aires; Alan Ridgway, Sprott Capital Partners; and Dr. Rahul Sarugaser, Paradigm Capital Inc.

Section 3: Therapeutic Area Focus
Chair: Dr. Rahul Sarugaser, Paradigm Capital

1:40 p.m.

Cannabinoids in Dermatology Dr. Elena Pope, The Hospital for Sick Children
Panelists: Dr. Mauricio Torres-Pradilla, Fundación Universitaria de Ciencias de la Salud; and Dr. Irene Lara-Corrales, The Hospital for Sick Children

2:20 p.m.

Cannabinoids in Epilepsy Dr. Amza Ali, University of the West Indies/Avicanna Inc.; and Dr. Peter Carlen, University of Toronto
Panelists: Dr. Peter Carlen, University of Toronto; Dr. Kevin Chapman, Children’s Hospital Colorado; Dr. Lawrence Hirsch, Yale University; and Dr. Blathnaid McCoy, The Hospital for Sick Children

3:00 p.m.


3:20 p.m.

Cannabinoids in Oncology Dr. Alejandro Berlin, Princess Margaret Cancer Centre
Panelists: Dr. Claudia Buitrago, Colombian Association of Palliative Care; Dr. Justin Grant, Princess Margaret Cancer Centre; and Dr. Zohar Koren, SciCann Therapeutics Inc.

4:00 p.m.

Cannabinoids in Pain Management Dr. Hance Clarke, University Health Network
Panelists: Dr. Robert Bonin, University of Toronto; Dr. Mohit Kapoor, University of Toronto; Dr. Sefi Kronenberg, The Hospital for Sick Children; and Dr. Karim Ladha, University Health Network

4:40 p.m.

Closing Remarks Aras Azadian, Chief Executive Officer and Chairman, Avicanna Inc.